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Abstract Phospholamban is the regulator of the Ca2+-ATPase 
in cardiac sarcoplasmic reticulum (SR). It is phosphorylated by 
a Ca2+lcalmodulin-dependeut protein kinase (SRCaM kinase) 
which is closely associated with cardiac SR membrane prepara- 
tions. We found that, upon renaturation of pig cardiac SR pro- 
teins, blotted onto PVDF membrane, two polypeptides of 54 and 
52 kDa showed Ca2+lcalmodulin-dependent au ophosphorylation. 
In Western blots of SR proteins, the 54/52 kDa polypeptides were 
recognized by an antibody specific for the &CaM kinase 
isoforms, but not by an anti-a-CaM kinase. The two polypeptides 
were selectively immunoprecipitated from solubilized SR vesicles 
with the anti-&CaM kinase. The CaM kinase inhibitors KN-62 
and peptide CaMK-(281-302) inhibited the activity of the 
SRCaM kinase with IC5o values in the same range with those 
obtained for the brain isozyme. In addition, initial auto- 
phosphorylation (Ca2+-dependent) produced a partially Ca2+-in - 
dependent enzyme while further autophosphorylation (CaZ+-inde- 
pendent) made the enzyme completely Ca2+-independent. Based 
on these results we suggest hat the SRCaM kinase is a distinct 
&CaM kinase isozyme. 
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1. Introduction 
Phospholamban (PLB) is a small pentameric protein com- 
plex [1] composed of identical subunits, each 52 amino acids 
long. PLB is proposed to be the key phosphoprotein in mediat- 
ing the heart's contractile responses to fl-adrenergic agonists, 
by regulating the activity of SERCA2a [2]. Dephosphorylated 
PLB is an inhibitor of SERCA2a while phosphorylation re- 
lieves the inhibitory effect. PLB has been shown to be 
phosphorylated, in vivo, during fl-adrenergic stimulation at 
Ser-16 and Thr-17 [3]. Phosphorylations of these two residues, 
in vitro, are being catalyzed by cAMP-dependent protein ki- 
nase and CaM kinase, respectively [4]. 
The CaM kinase is the major multisubstrate protein kinase 
that is activated by increases in intracellular Ca 2+ ion concen- 
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tration (for review [5]). The CaM kinase is composed of a family 
of isoforms derived from four (~,/~, 7/and ~ closely related 
genes. Isoforms range in size from 50-60 kDa (SDS-PAGE) 
and form homomultimers or heteromultimers of 6-12 subunits. 
Each CaM kinase isoform contains an amino terminal catalytic 
domain, a central regulatory domain and a carboxy terminal 
association domain. The predominant difference between the 
isoforms is their variable domain between the regulatory and 
association domains. A hallmark of CaM kinase is auto- 
phosphorylation which converts the kinase to a Ca2+-independ - 
ent enzyme. 
For a long time it was known that the cardiac SR contains 
an endogenous Ca2+/CaM-dependent kinase which phospho- 
rylates PLB [6]. Recently it was shown that this SRCaM kinase 
directly phosphorylates and activates SERCA2a, in addition to 
PLB [7,8]. Also, the CRC has been shown to be phosphorylated 
by the SRCaM kinase [7,9], although the physiological function 
of this later phosphorylation is not yet established. In skeletal 
muscle, phosphorylation of the CRC by the cytosolic CaM 
kinase leads to its activation while phosphorylation by the 
membrane bound CaM kinase leads to inhibition [10,11]. At- 
tempts to characterize this SRCaM kinase have been limited 
[12,13]. In view of the central role of SRCaM kinase in the 
regulation of Ca 2+ uptake and release by cardiac SR and the 
fact that the CaM kinase is a growing isozyme family we exam- 
ined whether the cardiac SRCaM kinase is a definite member 
of this family and of which subtype. Our results suggest hat 
it is a distinct a-CaM kinase isozyme with subunits two poly- 
peptides of 54 and 52 kDa, in approximately a 1 : 1 ratio. 
2. Materials and methods 
2.1. Materials 
Chemicals were obtained from the following sources: protein-A 
Sepharose CL-4B, Triton X-100, Syntide-2, anti-rabbit IgG-POD, 
cholic acid sodium salt, Sigma; Phosphocellulose (Pll), P81 filter 
paper, Whatman International; Leupeptin, soybean trypsin inhibitor, 
PMSF, DTT, Immobilon-P membrane, BSA (fraction V), Serva; Anti- 
mouse IgG-POD (fab fragments), anti-Ca2*/Calmodulin-dependent 
protein kinase II (anti-~), Boehringer-Mannheim; calmodulin-Sepha- 
rose 4B, Pharmacia; KN-62, Biomol; CaM kinase II inhibitor (281- 
302), RBI; anti-mouse IgG + IgA + IgM (H + L), Zymed; ECL West- 
ern blotting detection kit, [y-32p]ATP (spec.act. 3000 Ci/mmol), Amer- 
sham; Protein Phosphatase-2A was prepared according to [14]. Calm- 
odulin prepared according to [15] was a gift from Dr. I. Morano. 
CK2-DELTA (anti-6) affinity purified polyclonal antibody [16] was 
kindly provided by Dr. H. Singer (Geisinger Clinic, Danville, PA, 
USA). 
2.2. Purification of CaM kinase 
Rat brain kinase was purified according to [17] with minor modifica- 
tions. All subsequent s eps were carried out at 4°C. Forebrains from 
25 Wistar male rats were quickly removed and homogenized in a Tef- 
lon/glass homogenizer in Buffer A (1:10 w/v) containing 50 mM 
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HEPES (pH 7.5), 5 mM EGTA, 5 mM EDTA, 0.5 mM DTT, 0.3 mM 
PMSF, 10 mg/liter leupeptin and 40 mg/liter soybean trypsin inhibitor. 
The homogenate was centrifuged at 35,000 x g for 25 rain. The pellet 
was rehomogenized (1 :5 weight of original tissue/volume) in Buffer B 
and stirred slowly for 20 min. Buffer B was identical to Buffer A except 
for the following substitutions: 4 mM HEPES (pH 7.5), 0.5 mM EGTA, 
0.5 mM EDTA. The rehomogenized material was then centrifuged at 
35,000 x g for 25 min. The two 35,000 x g supernatants were pooled and 
centrifuged at 100,000 x g for 60 min. The resulting supernatant was 
filtered twice through glasswool, adjusted to 50 mM HEPES (pH 7.5) 
and then applied to a phosphocellulose column (20 g) that had been 
equilibrated in Buffer C: 50 mM HEPES (pH 7.5), 1 mM EGTA, 1 mM 
EDTA, 0.5 mM DTT, 0.3 mM PMSF, 5 rag/liter leupeptin and 20 
mg/liter soybean trypsin inhibitor. The column was washed with 2 
column volumes of Buffer C and then 10 column volumes of Buffer C 
containing 0.2 M NaC1. The kinase was eluted with Buffer C containing 
0.45 M NaC1. The active fractions (coincide with the protein peak) were 
pooled, adjusted to 50 mM HEPES (pH 7.5), 1 mM DTT, 0.6 mM 
CaCI2, 3 mM magnesium acetate, 10% (v/v) glycerol, 0.2 M NaCI and 
loaded to a CaM-Sepharose affinity column (10 ml) which had been 
previously equilibrated in Buffer D: 50 mM HEPES (pH 7.5), 0.2 M 
NaC1, 1 mM DTT, 0.6 mM CaCI 2 and 3 mM magnesium acetate. After 
washing the column with 10 volumes of Buffer D containing 0.8 M 
NaC1 the kinase was eluted with 50 mM HEPES (pH 7.5), 0.2 M NaC1, 
2 mM EGTA, 1 mM DTT and 1 mM magnesium acetate. The active 
fractions were pooled, dialyzed in 50 mM HEPES (pH 7.5), 50% (v/v) 
glycerol, 10% (v/v) ethylene glycol, 0.5 mM EDTA, 1 mM DTT and 
stored at -25°C. 
phosphorylation, was performed in the same manner, except hat after 
2 min of incubation a burst of Ca>-independent autophosphorylation 
was initiated by addition of excess EGTA (3.3 mM final) and the 
reaction was allowed to proceed for 1 min. 
2.7. Immunoprecipitation 
50/~g of SR membranes were autophosphorylated as escribed above 
(without BSA, at 30°C for 2 min) and the reaction was terminated by 
the addition of excess EDTA. Membrane proteins were solubilized with 
Buffer E (final concentrations: 25mM HEPES, pH 7.5, 0.1 M NaCI, 
0.5 mM EDTA, 0.5 mM EGTA, 30 mM NaF, 1% Triton X-100, 4 mM 
sodium cholate, 0.5 mM PMSF and 0.5 mM DTT) for 1 h at 4°C. 
Insoluble material was pelleted by centrifugation at 100,000 x g for 30 
min. The supernatant was diluted 10-fold with Buffer F (Buffer E 
diluted 10-fold including 0.1% BSA) and incubated overnight at 4°C 
with CK2-DELTA (or anti-~). The samples were further processed as 
described in [22]. When anti-~ was used the protein-A Sepharose CL-4B 
was pretreated with anti-mouse IgG + IgA + IgM. 
2.8. Electrophoresis, imrnunoblotting and autoradiography 
SDS-PAGE was performed according to [23] using 10% poly- 
acrylamide gels. For measurement of [32pIP i incorporation i to native 
PLB, SR proteins were separated on Urea/SDS gels [24]. Autora- 
diograms were quantitated with a PDI (NY, USA) densitometer o
bands of interest were cut out and counted by liquid scintillation. 
Immunoblotting was performed according to [25], using peroxidase 
conjugated secondary antibodies. Blots were developed using the ECL 
chemiluminescene kit.
2.3. Preparation of SR membranes 
A microsomal fraction enriched with SR vesicles from pig ventricular 
muscle was prepared according to [18] with the following modifications: 
(i) the homogenization buffer contained additionally 1 mg/liter 
leupeptin, 4 mg/liter soybean trypsin inhibitor and 0.2 mM PMSF; 
(ii) the final resulting pellet containing SR vesicles was suspended in 
buffer containing 10 mM HEPES (pH 7.2), 0.29 M sucrose, 0.1 M KC1 
and stored frozen (in small aliquots) in liquid N2. Under these condi- 
tions the SRCaM kinase activity was stable up to nine months. 
2.4. Synthetic peptide 
The PLB-peptide, corresponding toamino acids 2-25 of PLB (cyto- 
plasmic domain) according to the nomenclature given in [4,19] was 
synthesized by the solid phase method [20] and purified by reverse- 
phase HPLC on a Bischoft Polyencap 300 (10 mm particle size) column. 
The identity of the purified peptide was verified by amino acid analysis. 
Using the PLB-peptide as substrate for the SRCaM kinase, we obtained 
a specific activity of approximately 0.15/lmol PJmin/mg of SR protein. 
The Ca2+-independent ac ivity was minimal (0.5% of the total activ- 
ity). 
2.5. Activity assay 
The standard assay mixture contained, 50 mM HEPES (pH 7.5), 10 
mM magnesium acetate, 1mg/ml BSA, 35/.tM PLB-peptide, 0.1 mM 
[~'-32p]ATP (50 100/tCi//zmol) with 1 mM EGTA (Ca2+-independent 
activity) or with 0.4 mM CaC12 and 0.8 pM CaM (total activity) in a 
volume of 50/A. Reactions were initiated by addition of SR membranes 
(0.5-1/lg), incubated 1-2 min at 30°C and terminated by addition of 
TCA to final concentration of 2.5% (w/v). Precipitated protein was 
pelleted by centrifugation and 40/11 of the supernatant were spotted 
onto Whatman P81 phosphocellulose paper, followed by washing in 75 
mM phosphoric acid and counting Cerenkov radiation in a liquid 
scintillation counter [21]. The inhibition experiments with KN-62 were 
performed as described above except hat 0.15/tM CaM was used, and 
the reaction was initiated by addition of [7/-32p]ATP and CaM. 
2.6. Autophosphorylation 
5 ¢tg of cardiac SR membranes were preincubated in 50 mM HEPES 
(pH 7.5), 10 mM magnesium acetate, 1mg/ml BSA, 0.2 mM CaC12 and 
0.4 ¢tM CaM in the presence or absence of 0.1 mM ATP at 18°C. After 
2 min the reaction was terminated by 4-fold dilution with ice cold STOP 
buffer: 50 mM HEPES (pH 7.5), 1 mg/ml BSA, 20% ethylene glycol and 
10 mM EDTA. The activity of the autophosphorylated kinase was 
assayed immediately as described above. CaZ+-independent auto- 
2.9. Other methods 
Protein concentration was determined by the Bio-Rad protein bind- 
ing assay using bovine serum albumin as standard. In situ renaturation 
was performed as described in [26], including 5 ¢tM of unlabelled ATP 
in the phosphorylation buffer. 
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Fig. 1. Detection of CaM kinase activity, following in situ renaturation. 
Cardiac SR proteins were resolved on SDS-PAGE (10%), electroblot- 
ted onto Immobilon-P, and then renatured and phosphorylated in situ 
(in presence of Ca>/CaM). Lane 1:2.5/tg of purified brain CaM kinase 
(c~ and fl subunits) and lane 2:50 ¢tg of cardiac SR proteins. Molecular 
weight markers are given in kDa. 
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Fig. 2. Immunoreactivity of cardiac SR proteins with anti-~ and anti-~. (A) Western blotting. Lane 1: 0.2/zg of purified brain CaM kinase; lane 2 
and lane 3, 10/zg of cardiac SR proteins. (B) Immunoprecipitation. Lane 1, 5/lg of purified brain CaM kinase; lane 2 and lane 3, 50/zg of cardiac 
SR proteins. 
3. Results 
In order to identify polypeptides exhibiting Ca2+/CaM-de - 
pendent autophosphorylation activity in SR cardiac mem- 
branes, we adopted the in situ renaturation method, which 
detects CaM kinase activity after renaturation of proteins 
transferred from SDS-PAGE to PVDF membranes [26]. When 
autophosphorylation was performed in the presence of Ca2+/ 
CaM two polypeptides were detected, of 54 and 52 kDa (Fig. 
1, lane 2). Under the same experimental conditions the brain 
CaM kinase showed two bands (Fig. 1, lane 1), of 50 kDa 
(c~-subunit) and 60 kDa (fl-subunits). In the absence of Ca2+/ 
CaM no signal was detected (not shown). 
When SR proteins were immunoblotted using anti-& two 
highly cross-reactive bands were observed (Fig. 2A, lane 3), 
corresponding to the above identified polypeptides of 54/52 
kDa. Also, in immunoprecipitation of solubilized SR proteins 
the anti-~ precipitated specifically the 54/52 kDa polypeptides 
(Fig. 2B, lane 3). A monoclonal antibody for the c~-subunit of 
the brain CaM kinase (Fig. 2A and B, lanes 1) did not cross- 
react with SR proteins in immunoblotting (Fig. 2A, lane 2) and 
did not recognize solubilized SR proteins in immunoprecipita- 
tion (Fig. 2B, lane 2). Quantitation of the signals (integrated 
peak area) corresponding to the 54/52 kDa polypeptides from 
Western blotting, immunoprecipitation and in situ renaturation 
gives a relative ratio 1 : 1, suggesting that the two polypeptides 
are present in cardiac SR membranes in equal molar ratio. 
Next we examined the effects of two CaM kinase inhibitors, 
KN-62 and peptide CaMK-(281-302), on the SRCaM kinase 
activity. The activity was measured by assaying PLB-peptide 
phosphorylation. The ICso values obtained were 7 and 10/~M 
for KN-62 and peptide CaMK-(281-302), respectively. Similar 
ICs0 values were obtained when syntide-2 or endogenous PLB 
were used as substrates. 
The activity of the SRCaM kinase in its dephosphorylated 
state (Fig. 3, control) ranges from 0.5% (Ca2+-independent ac- 
tivity) to 100% (total activity). Autophosphorylation (i  pres- 
ence of CaZ+/CaM) generates a partially CaZ+-independent 
form, with Ca2+-independent ac ivity of 25% (Fig. 3, partial). 
Additional autophosphorylation (in presence of excess EGTA) 
creates a second form of SRCaM kinase with suppressed total 
activity of 23% (Fig. 3, complete). Treatment of the two auto- 
phosphorylated forms with PP-2A (i) results in reduction of the 
Ca2÷-independent ac ivity to 7% and 4.5% (Fig. 4, partial and 
complete, respectively), and (ii) partially restores the sup- 
pressed total activity to 55% (Fig. 4, complete). 
4. Discussion 
It is known that the selective inhibitor of CaM kinase, KN- 
62, inhibits competitively with Ca2+/CaM by directly binding to 
the CaM binding site of CaM kinase [27]. We obtained an ICs0 
value of 7/tM for the SRCaM kinase which is in the same range 
with the ICs0 value obtained for the brain CaM kinase 0.5/zM 
[28]. We can assume that the SRCaM kinase contains a CaM 
binding site similar to that of the CaM kinase. 
74 
The autoinhibitory domain of brain CaM kinase (residues 
281-309) interacts with elements of the catalytic domain to 
suppress the phosphotransferase ctivity of the kinase [29]. In 
order to examine if the SRCaM kinase contains a similar auto- 
inhibitory segment, we used the peptide CaMK-(281 302), 
which represents the minimum autoinhibitory segment of or- 
CaM kinase and does not significantly bind Ca2+/CaM. We 
obtained an ICs0 value of 10 pM which is similar to that ob- 
tained for the brain CaM kinase, 8 pM [30]. This result indi- 
cates that the SRCaM kinase does have an autoinhibitory do- 
main in the same region as the ~-subunit. 
Autophosphorylation is likely the most important mecha- 
nism regulating CaM kinase activity, following stimulation by 
CaZ+/CaM. Initial autophosphorylation of SRCaM kinase ex- 
hibits a requirement for Ca2+/CaM and generates a partially 
CaZ+-independent form of the kinase (Fig. 3, partial) with little 
loss in total activity, probably due to some thermal instability 
[31]. Once some Ca2+-independent ac ivity has been generated 
by initial autophosphorylation additional autophosphorylation 
proceeds in the absence of Ca2+/CaM giving rise to inhibition 
of total activity and a completely Ca2+-independent form (Fig. 
4, complete). Addition of excess EGTA causes CaM to dissoci- 
ate from the SRCaM kinase, thereby unmasking new auto- 
phosphorylation site(s). Therefore, the site(s) responsible for 
the suppression of the total activity should lie within the CaM 
binding domain of SRCaM kinase. PP-2A reduces the Ca 2+- 
independent activity and partially restores the inhibited total 
activity (Fig. 4). 
Our results are consistent with the proposed model for the 
regulation of the brain CaM kinase by autophosphorylation [5]. 
It states that autophosphorylation results in multisite phos- 
phorylation and separate autophosphorylation sites are re- 
sponsible for (i) generation of Ca2+-independent ac ivity, and 
(ii) suppression of total activity. Dephosphorylation by protein 
phosphatases regenerates the native nzyme. The sites responsi- 
ble for inhibition of the total activity of CaM kinase lie within 
its CaM binding domain [32]. 
The polypeptides of 54 and 52 kDa are the only cardiac SR 
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Fig. 3. Effects of autophosphorylation of SRCaM kinase on activity. 
Preincubation of cardiac SR membranes (5 pg) to allow auto- 
phosphorylation was performed with unlabelled ATP (100 pM) and the 
effect of autophosphorylation assessed by substrate (PLB-peptide) 
phosphorylation. Open bars represent total activity and dark bars Ca 2÷- 
independent activity. Control, preincubation without ATP; partial, 
Ca2+-dependent au ophosphorylation; c mplete, Ca2+-independent au- 
tophosphorylation (as described in section 2). Kinase activity + S.D. of 
triplicate determinations is represented as % activity. 100% activity is 
defined as that determined inthe presence of Ca2+/CaM for the control 
(-ATP). 
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Fig. 4. Reversal of the effects of autophosphorylation by PP-2A. Phos- 
phatase storage buffer (-) or PP-2A (+), were added to both forms 
(partial and complete) of autophosphorylated SRCaM kinase. Incuba- 
tion was for 2 min at 30°C, aliquots were removed, iluted with ice-cold 
STOP buffer and kinase activities assayed as described in legend to Fig. 
3. Open bars represent total activity and dark bars Ca2+-independent 
activity. Kinase activity + S.D. of triplicate determinations is repre- 
sented as % activity. 
proteins exhibiting Ca2+/CaM-dependent au ophosphorylation 
and high cross-reactivity with the anti-& So far, cDNA clones 
for four isoforms (52, 53, 56 and 57) all splice variants of the 
5-subunit have been detected in cardiac tissue [16,33]. The 
CK2-DELTA antibody is made to a 12 amino acid peptide 
from the unique C-terminus of the 5-subunit [16]. It recognizes 
all 5-subunit splice variants which have this C-terminus. Thus, 
we have to exclude 56 and 57 as candidate subunits for the 
SRCaM kinase, since they have a deleted C-terminus [33]. Re- 
combinant 53 and 52 CaM kinaes isoforms purified from trans- 
fected COS-7 cells exhibit relative molecular masses of 54 and 
52 kDa (from SDS-PAGE), respectively [34]. These values coin- 
cide with the relative molecular masses of the two polypeptides 
we have identified in our study, as the subunits of the SRCaM 
kinase. 
Subcellular targeting of CaM kinase heteromultimers is be- 
lieved to be determined by the ratio of the subunits. Excess of 
53-isoform targets the holoenzyme to the nucleus, while excess 
of 52-isoform targets the holoenzyme to the cytosol [36]. Addi- 
tional evidence in support of this hypothesis, is provided from 
studies on the subcellular distribution of the brain CaM kinase, 
where the relative ratio of its subunits (~:fllfl') determines the 
subcellular localization of the holoenzyme [37]. Therefore, we 
propose that the CaM kinase heteromultimer containing an 
equal ratio of 53 and 52 subunits is targeted to cardiac SR 
membranes and is the SRCaM kinase identified in the present 
study. 
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